Dual diagnosis with substance use disorders (SUDs) consistently contributes to the premature mortality and increased disability observed in schizophrenia. Large genome-wide association studies are providing the information needed to investigate the genetic architecture of psychiatric disorders. Here, we discuss recent genetic investigations of dual diagnosis (i.e., schizophrenia plus a SUD) and how these findings can inform public health messages.
CITATION STYLE
Polimanti, R., Agrawal, A., & Gelernter, J. (2017, March 21). Schizophrenia and substance use comorbidity: A genome-wide perspective. Genome Medicine. BioMed Central Ltd. https://doi.org/10.1186/s13073-017-0423-3
Mendeley helps you to discover research relevant for your work.